Literature summary for 3.3.2.10 extracted from

Revermann, M.; Schloss, M.; Barbosa-Sicard, E.; Mieth, A.; Liebner, S.; Morisseau, C.; Geisslinger, G.; Schermuly, R.T.; Fleming, I.; Hammock, B.D.; Brandes, R.P.
Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice (2010), Arterioscler. Thromb. Vasc. Biol., 30, 909-914.

Search for more literature for 3.3.2.10

Protein Variants

Protein Variants	Comment	Organism
additional information	genetic deletion of soluble epoxide hydrolase attenuates the inflammatory response in the femoral cuff model, overview	Mus musculus

Inhibitors

Inhibitors	Comment	Organism	Structure
12-(3-adamantan-1-yl-ureido)dodecanoic acid	i.e. AUDA	Mus musculus

Natural Substrates/ Products (Substrates)

Natural Substrates	Organism	Comment (Nat. Sub.)	Natural Products	Comment (Nat. Pro.)	Rev.	Reac.
(5Z,8Z,11Z)-14,15-epoxyeicosatrienoic acid + H2O	Mus musculus	i.e. 14,15-EET, EETs have antiinflammatory effects and are required for normal endothelial function	(5Z,8Z,11Z)-14,15-dihydroxyeicosatrienoic acid	-	?

Organism

Organism	UniProt	Comment	Textmining
Mus musculus	P34914	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
artery	-	Mus musculus	-
connective tissue	-	Mus musculus	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
(5Z,8Z,11Z)-14,15-epoxyeicosatrienoic acid + H2O	-	Mus musculus	(5Z,8Z,11Z)-14,15-dihydroxyeicosatrienoic acid	-	?
(5Z,8Z,11Z)-14,15-epoxyeicosatrienoic acid + H2O	i.e. 14,15-EET, EETs have antiinflammatory effects and are required for normal endothelial function	Mus musculus	(5Z,8Z,11Z)-14,15-dihydroxyeicosatrienoic acid	-	?

Synonyms

Synonyms	Comment	Organism
SEH	-	Mus musculus

General Information

General Information	Comment	Organism
malfunction	soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice	Mus musculus

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)